Viatris Healthcare GmbH
- Legal form
- GmbH
- Seat
- Bad Homburg, Germany
Based on the notices and sources Inteliwert covers; not a complete record. Last checked 1 February 2026.
Identifiers
As the covered sources state them.
- Register entry
- HRB 15331
Track record in public tenders
Awards in the covered notices over the last 36 months, per CPV division.
| CPV division | Awards | Award value (excl. VAT) | Buyers | Repeat buyers | First award | Last award |
|---|---|---|---|---|---|---|
| 33 Medical equipments, pharmaceuticals and personal care products | 1 | — | 1 | 0 | 1 November 2024 | 1 November 2024 |
Awards
- Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Betahistin, ATC N07CA01 für die Zeit 01.02.26 - 31.01.28 (zzgl. Verlängerungsoption 1x12 Monate)Buyer: DAK-Gesundheit · Awarded: 1 February 2026 · CPV 33600000
- Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Absatz 8 SGB V zum Wirkstoff Nadroparin, ATC B01AB06 für die Zeit 01.11.2024 - 31.10.2026Buyer: DAK-Gesundheit · Awarded: 1 November 2024 · CPV 33600000
- Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Absatz 8 SGB V zum Wirkstoff Abirateron (ausgenommen Wirkstärke 500 mg), ATC L02BX03 für die Zeit 01.10.2024 - 30.09.2026Buyer: DAK-Gesundheit · Awarded: 1 October 2024 · CPV 33600000
Certifications and prequalification
No certification or prequalification found in the covered sources.
A certification missing here is unknown, not absent.
Website and LinkedIn
Not found in the indexed notices.
Open tenders that might fit
Possible match based on public information
Companies Inteliwert knows from its sources, not the whole market. Inteliwert does not judge eligibility, fit or chances.
-
OpenTenderEstablished supplier
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Natalizumab (ATC-Code nach WHO: L04AG03)
Reasons
- Won a contract in CPV group 336 (2026-02-01) Evidence · checked 7 Nov 2026
- Seat in the same country as the place of performance Evidence · checked 7 Nov 2026
- 3 awards in this field in 36 months, from 1 buyer Evidence · checked 7 Nov 2026
Last checked 6 Nov 2026, 23:30 (UTC+01:00)Official notice -
OpenTenderEstablished supplier
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Apixaban (ATC-Code nach WHO: B01AF02)
Reasons
- Won a contract in CPV group 336 (2026-02-01) Evidence · checked 7 Nov 2026
- Seat in the same country as the place of performance Evidence · checked 7 Nov 2026
- 3 awards in this field in 36 months, from 1 buyer Evidence · checked 7 Nov 2026
Last checked 6 Nov 2026, 23:30 (UTC+01:00)Official notice
Is this your company?
Send corrections, or ask us to remove the profile, to hello@inteliwert.com. You can also ask that the company never be tagged on LinkedIn.
About this profile
Each fact on this page shows its source: a public notice, an open-data register (GLEIF, Wikidata) or the company’s own website. Inteliwert does not rate companies and does not judge eligibility, fit or chances.
Based on the notices and sources Inteliwert covers; not a complete record.
Last checked 1 February 2026.